Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
The British Journal of Radiology|January 19, 2018
Changes in radiotherapy fractionation-breast cancerJohn Yarnold
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 31, 2009
Accelerated partial breast irradiation trials: diversity in rationale and designMariella Mannino, John Yarnold
Acta Oncologica (Stockholm, Sweden)|October 19, 2010
Hypofractionated adjuvant whole breast radiotherapy: progress and prospectsJohn Yarnold, Joanne Haviland
The Lancet. Oncology|April 4, 2009
Effect of breast-duct anatomy and wound-healing responses on local tumour recurrence after primary surgery for early breast cancerMariella Mannino, John Yarnold
Breast (Edinburgh, Scotland)|June 1, 2010
Pushing the limits of hypofractionation for adjuvant whole breast radiotherapyJohn Yarnold, Joanne Haviland
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 5, 2010
Pathogenetic mechanisms in radiation fibrosisJohn Yarnold, Marie-Catherine Vozenin Brotons
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 20, 2012
The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapyYat Tsang, Joanne Haviland, Karen Venables, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 11, 2013
Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapyNavita Somaiah, John Yarnold, Anne Lagerqvist, et al.
Journal of Magnetic Resonance Imaging : JMRI|March 26, 2003
Dynamic MRI of breast hardness following radiation treatmentAnwar R Padhani, John Yarnold, Jane Regan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2011
Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?Christy Goldsmith, Joanne Haviland, Yat Tsang, et al.
Pageof 5